Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Regen BioPharma (RGBP) over the last 12 years, with Q4 2025 value amounting to 27.73.

  • Regen BioPharma's Equity Ratio rose 655.01% to 27.73 in Q4 2025 from the same period last year, while for Dec 2025 it was 27.73, marking a year-over-year increase of 655.01%. This contributed to the annual value of 22.87 for FY2025, which is 2938.5% up from last year.
  • Per Regen BioPharma's latest filing, its Equity Ratio stood at 27.73 for Q4 2025, which was up 655.01% from 22.87 recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Equity Ratio registered a high of 8.66 during Q2 2021, and its lowest value of 121.66 during Q1 2022.
  • Over the past 5 years, Regen BioPharma's median Equity Ratio value was 25.3 (recorded in 2025), while the average stood at 27.07.
  • As far as peak fluctuations go, Regen BioPharma's Equity Ratio skyrocketed by 9034.29% in 2021, and later plummeted by 32709.4% in 2022.
  • Quarter analysis of 5 years shows Regen BioPharma's Equity Ratio stood at 13.27 in 2021, then rose by 11.1% to 11.8 in 2022, then plummeted by 178.54% to 32.86 in 2023, then grew by 9.7% to 29.67 in 2024, then rose by 6.55% to 27.73 in 2025.
  • Its Equity Ratio was 27.73 in Q4 2025, compared to 22.87 in Q3 2025 and 29.55 in Q2 2025.